cytarabine has been researched along with goralatide in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 8 (72.73) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carde, P; Chastang, C; Corbion, O; Delwail, V; Ferrero, JM; Goncalves, E; Isnard, F; Mathieu-Tubiana, N; Vekhoff, A; Vuillemin, E | 1 |
| Frindel, E; Masse, A; Pradelles, P; Rigaud, M; Volkov, L | 1 |
| Bogden, AE; Carde, P; de Paillette, ED; Frindel, E; Moreau, JP; Tubiana, M | 1 |
| Frindel, E; Lopez, M; Pradelles, P; Wdzieczak-Bakala, J | 1 |
| Bony, V; Frindel, E; Lopez, M; Pradelles, P; Wdzieczak-Bakala, J | 1 |
| Frindel, E; Guittet, E; Lenfant, M; Prome, JC; Sotty, D; Wdzieczak-Bakala, J | 1 |
| Bogden, AE; Carde, P; Deschamps de Paillette, E; Frindel, E; Gamba-Vitalo, C; Moreau, JP; Tubiana, M | 1 |
| Deschamps de Paillette, E; Filipski, E; Lévi, F; Li, XM; Soulard, C | 1 |
| Aidoudi, S; Caen, JP; Drouet, V; Guigon, M; Han, ZC | 1 |
| Briscoe, CV; Chisi, JE; Ezan, E; Genet, R; Riches, AC; Wdzieczak-Bakala, J | 1 |
| Barbier, M; Bignon, J; Boutonnat, J; Colle, PE; Faussat, AM; Marie, JP; Ronot, X; Thierry, J; Wdzieczak-Bakala, J | 1 |
1 trial(s) available for cytarabine and goralatide
| Article | Year |
|---|---|
[Seraspenide (acetylSDKP): phase I-II trial study of inhibitor of hematopoiesis protects against toxicity of aracytine and ifosfamide monochemotherapies].
Topics: Cytarabine; Double-Blind Method; Hematopoiesis; Humans; Ifosfamide; Oligopeptides | 1992 |
10 other study(ies) available for cytarabine and goralatide
| Article | Year |
|---|---|
Correlation of endogenous acetyl-ser-asp-lys-pro plasma levels in mice and the kinetics of pluripotent hemopoietic stem cells entry into the cycle after cytosine arabinoside treatment: fundamental and clinical aspects.
Topics: Animals; Cell Cycle; Cytarabine; Hematopoietic Stem Cells; Mice; Mice, Inbred CBA; Oligopeptides | 1992 |
Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation.
Topics: Animals; Body Weight; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line; Cyclophosphamide; Cytarabine; Female; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Immunologic Deficiency Syndromes; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Oligopeptides; Transplantation, Heterologous | 1991 |
Human placental low molecular weight factors inhibit the entry into cell cycle of murine pluripotent stem cells.
Topics: Amino Acid Sequence; Animals; Cell Cycle; Chromatography; Chromatography, High Pressure Liquid; Cytarabine; Female; Hematopoietic Stem Cells; Hydroxyapatites; Immunoenzyme Techniques; Mice; Mice, Inbred CBA; Molecular Sequence Data; Molecular Weight; Oligopeptides; Placenta; Placental Extracts | 1991 |
A low-molecular-weight factor extracted from human placenta inhibits the entry into cell cycle of murine pluripotent stem cells.
Topics: Animals; Cell Cycle; Chromatography, High Pressure Liquid; Cytarabine; DNA Replication; Female; Hematopoietic Stem Cells; Mice; Molecular Weight; Oligopeptides; Placenta; Pregnancy; Tissue Extracts | 1991 |
Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure.
Topics: Animals; Bone Marrow; Cattle; Cell Cycle; Cell Division; Chromatography, High Pressure Liquid; Cytarabine; DNA Replication; Fetus; Hematopoietic Stem Cells; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Inbred BALB C; Oligopeptides; Solvents | 1989 |
Goralatide (AcSDKP), a negative growth regulator, protects the stem cell compartment during chemotherapy, enhancing the myelopoietic response to GM-CSF.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Feasibility Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Growth Inhibitors; Hematopoietic Stem Cells; Leukocyte Count; Leukopenia; Leukopoiesis; Mice; Oligopeptides; Platelet Count; Time Factors | 1998 |
Circadian-based effects of AcSDKP, with or without rhG-CSF on hematologic toxicity of chemotherapy in mice.
Topics: Analysis of Variance; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blood Cell Count; Bone Marrow; Carboplatin; Circadian Rhythm; Cytarabine; Granulocyte Colony-Stimulating Factor; Growth Inhibitors; Humans; Male; Mice; Oligopeptides | 1998 |
The tetrapeptide AcSDKP reduces the sensitivity of murine CFU-MK and CFU-GM progenitors to aracytine in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Count; Cell Division; Cell Survival; Cytarabine; Growth Inhibitors; Hematopoietic Stem Cells; Male; Mice; Mice, Inbred BALB C; Oligopeptides; Time Factors | 1998 |
Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antimetabolites, Antineoplastic; Captopril; Cell Division; Cell Line; Cells, Cultured; Cytarabine; Hematopoietic Stem Cells; Interleukin-3; Leukemia, Myeloid; Macrophage Colony-Stimulating Factor; Mice; Mice, Inbred Strains; Oligopeptides; Peptidyl-Dipeptidase A; Recombinant Proteins; S Phase | 2000 |
Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.
Topics: Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bromodeoxyuridine; Cell Proliferation; Cytarabine; Daunorubicin; DNA; Etoposide; Flow Cytometry; Fluorescent Dyes; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydrocarbons, Chlorinated; Leukemia; Leukemia, Myeloid, Acute; Microscopy, Fluorescence; Oligopeptides; Organic Chemicals; Radiation-Protective Agents | 2005 |